Lv4
574 积分 2024-08-09 加入
[Chinese expert consensus on the systemic treatment of advanced clear cell renal cell carcinoma (2024 edition)]
1个月前
已完结
IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study
2个月前
已完结
Therapeutic potential of [177Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment
2个月前
已完结
[Chinese expert consensus on treatment of malignant pleural effusion (2023 Edition)]
2个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
2个月前
已完结
Expression of TRAIL and TRAIL receptors in normal and malignant tissues
2个月前
已完结
2025 FDA approvals
3个月前
已完结
The clinical significance and potential molecular mechanism of integrin subunit beta 4 in laryngeal squamous cell carcinoma
4个月前
已完结
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial
4个月前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
